Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
Is GSK PLC Sponsored ADR (GSK) Stock Outpacing Its Medical Peers This Year?
11:18am, Monday, 04'th Dec 2023
Here is how GSK (GSK) and Acadia Pharmaceuticals (ACAD) have performed compared to their sector so far this year.
These biotechs targeting multiple neurodegenerative diseases
08:15am, Friday, 01'st Dec 2023
Anyone who has struggled with a neurodegenerative disease (NDD) or has cared for someone who has one of these illnesses knows how challenging they are to treat and even diagnose. NDDs damage cognitive
GSK plc (GSK) Presents at Redburn Atlantic CEO Conference (Transcript)
03:16pm, Wednesday, 29'th Nov 2023
GSK plc (NYSE:GSK ) Redburn Atlantic CEO Conference November 29, 2023 4:00 AM ET Company Participants Luke Miels - Chief Commercial Officer Conference Call Participants Simon Baker - Redburn Simon Bak
GSK plc (GSK) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)
12:33pm, Wednesday, 29'th Nov 2023
GSK plc (NYSE:GSK ) 6th Annual Evercore ISI HealthCONx Conference November 29, 2023 7:30 AM ET Company Participants Jeff McLaughlin - Director, Investor Relations Philip Dormitzer - SVP and Global Hea
GSK's Blenrep Combo Meets PFS Endpoint in Head-to-Head Study
03:02pm, Monday, 27'th Nov 2023
GSK announces positive data from the DREAMM-7 head-to-head phase III study evaluating Blenrep for second-line treatment of relapsed or refractory multiple myeloma. The study meets its primary endpoint
GSK Key Drugs & Vaccines Help Stock Outperform Industry YTD
09:47am, Monday, 27'th Nov 2023
Strong sales growth of GSK's specialty drugs and vaccines, the contribution from new products and positive pipeline updates are expected drive the stock in the future quarters.
3 Great Foreign Companies to Invest in Right Now
08:44am, Monday, 27'th Nov 2023
Adyen is a fast-growing fintech business. GSK is a major pharmaceutical company, delivering billions of vaccine doses, among other things.
GSK myeloma drug shows promise in hard-to-treat patient group
03:35am, Monday, 27'th Nov 2023
In a significant development for patients battling multiple myeloma, a type of blood cancer, GSK PLC (LSE:GSK, NYSE:GSK) has announced encouraging results from its latest phase III trial, named DREAMM
GSK says blood cancer drug meets primary goal in late-stage trial
02:17am, Monday, 27'th Nov 2023
British drugmaker GSK said on Monday its blood cancer drug Blenrep, when used as a second-line treatment, had met its primary goal of progression free survival in a late-stage trial.
Cameroon receives first shipment of GSK's Mosquirix malaria vaccine
05:18am, Wednesday, 22'nd Nov 2023
Cameroon received its first shipment of Mosquirix malaria vaccines manufactured by British drugmaker GSK Plc late on Tuesday, as the nation struggles with the mosquito-borne disease that kills more th
Dividend Income Update October 2023
08:05pm, Tuesday, 14'th Nov 2023
Without rehashing the wild ride we experienced in the market the last couple of months with triple digit gains and losses, I could find comfort in one thing, my dividends. Dividends may not increase e
GSK receives EU regualtory boost for bone marrow cancer drug
03:29am, Monday, 13'th Nov 2023
GSK PLC (LSE:GSK, NYSE:GSK) has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for its drug, momelotinib, a treatment for
EU regulator backs GSK's bone marrow cancer therapy
02:18am, Monday, 13'th Nov 2023
British drugmaker GSK on Monday said the human medicines committee of the European Medicines Agency had recommended approving its oral therapy to treat anaemia in patients with a type of bone marrow c
GSK valuation remains compelling vs pharma, says broker
10:46am, Thursday, 09'th Nov 2023
Arexvy, GSK's recently launched respiratory syncytial virus (RSV) vaccine, has made a strong start but management remained cautious given the recent launch and broker Berenberg says this is understand
GSK is a remedy for the winter investment blahs
10:35am, Tuesday, 07'th Nov 2023
GSK NYSE: GSK is not immune to the patent cliff faced by the pharmaceutical industry, but it is about as well prepared as it can be. The company faces a smaller impact than others, has years to go bef
